Solid doses first patient on Phase 3 trial

Today, Solid Biosciences announced that the first participant has been dosed in the Phase 3 Impact Duchenne clinical trial, a randomised, double-blind, placebo-controlled study evaluating SGT-003 for Duchenne. Clinical trial sites are currently active in Australia and...

Solid announces positive clinical update

Solid Biosciences has announced a positive clinical update on the SGT-003 gene therapy programme. This update includes interim safety and biomarker data from the ongoing Phase 1/2 Inspire Duchenne clinical trial. To date, 40 participants have been dosed with SGT-003...

Solid shares update on Inspire Duchenne clinical trial

Solid Biosciences has released an update on its Inspire Duchenne clinical trial, which is investigating the safety, tolerability and efficacy of its gene therapy candidate SGT-003. The Phase 1/2, open-label study has now dosed 23 patients, and expects to have dosed 30...

Duchenne community campaigns for givinostat

The UK’s National Institute for Health and Care Excellence (NICE) has announced it will seek further guidance on whether new treatment givinostat should be made routinely available on the NHS. NICE held its initial committee meeting to appraise the drug in July,...

Update on gene therapy Elevidys

Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns. The request followed three deaths potentially related to the gene therapy products. The deaths appeared to...

Solid reports positive clinical trial data

Solid Biosciences has shared positive clinical data for the first three patients in its Inspire Duchenne clinical trial. They have been dosed with Solid’s next generation gene therapy, known as SGT-003. Biopsy data at day 90 showed average microdystophin...

Solid begins dosing next-generation gene therapy

We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US – Nationwide Children’s Hospital in Columbus, Ohio,...

Pfizer provides update on gene therapy trial

Pfizer has announced that its mini-dystrophin gene therapy has not met its primary or secondary endpoints. Click here to read Pfizer’s update on Phase 3 of CIFFREO, a randomised double-blind placebo-controlled study in ambulatory boys aged 4-7. The primary...

Vamorolone approved in the EU

The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is approved for all people with Duchenne, irrespective of their underlying...